NEW YORK (GenomeWeb) – Seattle-based cancer immunotherapy company Juno Therapeutics has acquired AbVitro of Boston for approximately $78 million in cash and almost 1.3 million shares of its stock, the company said today.

In addition, Juno and Celgene have agreed in principle on a deal under which Celgene will license a subset of AbVitro's technology and have options to certain potential products deriving from it.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.